Mapping Endpoints: How to build an ALS clinical trial
Differing endpoint and efficacy expectations can make designing an ALS clinical trial challenging. Clinical Trials Arena looks at ways to dampen drug development obstacles.
By
William Newton
William Newton is a reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on rare diseases, Covid-19 antivirals, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Sage and Biogen’s depression drug iffy on efficacy despite dosing, safety upside
In a crowded antidepressant field, zuranolone’s fast onset and sustained effect might not be enough to mask its so-so…
By
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
By
Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial
As breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
By
Retrotope eyes $100m raise for neurodegenerative disease platform
California-based Retrotope aims to expand its investor pool as it prepares to potentially go public in the coming years.
By
The incomplete safety data on Aduhelm’s brain swelling side effect
Apparent data gaps for Biogen’s Aduhelm raise questions over the long-term safety of the newly approved Alzheimer’s disease drug.
By
BioMarin’s growth-accelerating drug for dwarfism will face scrutiny from European payers
Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the first drug approved for dwarfism.
By
Medicare’s National Coverage Determination could boost chances of limited Aduhelm coverage despite backlash
Could Medicare’s rare move to determine Aduhelm’s coverage nationally be a positive sign for Biogen?
By
Aerie’s eye drop for dry eyes has promising target but trial design a possible spoiler
The cooling sensation from Aerie’s eye drop is designed to trigger tear production in dry eye syndrome.
By